1 of 1
Story summary
- Scientists at the University of Barcelona and the University of Oregon created PPRH molecules that silence PCSK9.
- In HepG2 cells, HpE12 cut PCSK9 RNA by 74 % and protein by 87 %, raising LDL-receptor levels.
- A single HpE12 injection lowered plasma PCSK9 50 % and cholesterol 47 % in human-PCSK9 mice within three days.
- The authors say PPRHs are cheap, stable and non-immunogenic, which may avoid statin-related muscle side effects.
